newsfilter
← Earnings
Earnings Releases·

Perspective Therapeutics — 3Q 2026 Earnings Summary

  • Cash and investments rose to $202 million as of September 30, 2026, from $145 million at year-end 2025, while net loss widened to $32.4 million ($0.27/share) from $26.0 million ($0.35/share) in the prior year period.
  • Strategic milestones include a September 2026 collaboration with Merck to evaluate PSV359 with Keytruda®, FDA Fast Track designation for PSV359 in October 2026, and European orphan designation for bamzireotide in July 2026.
  • Management projects cash sufficiency to fund operations through 2028, with manufacturing site completion and an end-of-Phase 2 FDA meeting targeted for early 2027.
  • Clinical progress includes completed enrollment for bamzireotide's NET dose-finding cohort, advancement of PSV359 into its third dose cohort, and ongoing recruitment for lapemelanotide monotherapy.
Company
PERSPECTIVE THERAPEUTICS INC
Sector
Healthcare
Industry
Medical Devices